Dupilumab in the treatment of severe uncontrolled chronic rhinosinusitis with nasal polyps (CRSwNP): a multicentric observational phase 4 real-life study (DUPIREAL).

Eugenio De CorsoErnesto PasquiniMatteo TrimarchiIgnazio La MantiaFabio PagellaGiancarlo OttavianoMassimiliano GarzaroCarlotta PipoloSara TorrettaVeronica SecciaElena CantoneAndrea CiofaloDaniela LucidiGian Luca FaddaPia Clara PafundiStefano SettimiClaudio MontuoriFrancesca AnastasiGiulio PagliucaAngelo GhidiniCarlo CavaliereMarianna MaffeiFrancesco BussuStefania GalloFrank Rikki Mauritz CanevariGaetano PaludettiJacopo Gallinull null

Published in: Allergy (2023)

Our findings from this large-scale real-life study support the effectiveness of dupilumab as add-on therapy in patients with severe uncontrolled CRSwNP in reducing polyp size and improving the quality of life, severity of symptoms, nasal congestion, and smell.

Keyphrases

chronic rhinosinusitis
randomized controlled trial
atopic dermatitis
early onset
mesenchymal stem cells
bone marrow
cell therapy
sleep quality